SCOTTSDALE, Ariz., May 20 /PRNewswire/ — Regenesis Biomedical, Inc., a medical technology company that markets the Provant(R) Wound Therapy System, announced today the formation of a Scientific Advisory Board. The Board’s purpose is to guide advanced scientific investigations into the mechanism of action of Provant, new product development, and further application of Regenesis’ platform technology to clinical and industrial applications.
(Photo: )
“This is another milestone in Regenesis’ strategic plan to advance the science of wound care,” said Virginia Rybski, Acting President of Regenesis. “Our Scientific Advisory Board is composed of academics and thought leaders who are experts in the field of bioelectrochemistry, which is the interaction between energy and living systems. This group will assist in our evidenced- based decision-making as we further expand our platform technology into next generation products.”
The Regenesis Scientific Advisory Board brings together experts recognized in their fields:
* Metin Akay, Ph.D., Professor and Chairman of the Harrington Department
of Bioengineering at Arizona State University, and founding chairman of
the International IEEE Conference on Neural Engineering.
* Hunt Dabney, President, Hunt Dabney & Associates. Leading expert in
precision medical electronics and regulatory compliance mitigation.
Holds 7 US patents with 7 patents pending.
* Colin McCaig, Ph.D., Professor of Physiology and Head of School of
Medical Sciences at the University of Aberdeen, Scotland. Researches
role of endogenous direct current electrical fields in development and
regeneration of tissues in cell culture, excised tissues and whole
animals.
* Dennis Orgill, M.D., Ph.D., Associate Professor at Harvard Medical
School, Associate Chief of Plastic Surgery and Principal Investigator
of the Wound Healing and Tissue Engineering Laboratory at Brigham and
Women’s Hospital.
About the Provant Wound Therapy System
Provant delivers cell proliferation induction(R) (CPI(R)) therapy based on Regenesis’ proprietary pulsed radio frequency energy (PRFE) core technology platform. PRFE uses an optimized radiofrequency signal to stimulate dormant cells, causing them to replicate and to produce natural growth factors and other gene expression products, which facilitate reduction of the pain and edema associated with post-operative wound healing in soft tissues. We believe Provant is effective, economical, and easy-to-use.
About Regenesis Biomedical
Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. Regenesis developed, patented, and now markets the Provant Wound Therapy System. Our customers include health care facilities and providers that serve patients with wounds being treated by acute care hospitals, long- term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics.
Contact:
Regenesis Biomedical, Inc.
Media: Scott Robey, VP Marketing
Clinicians: Rick Isenberg, MD, VP Clinical Affairs
Investors: Virginia Rybski, Acting President
480-970-4970
Regenesis Biomedical, Inc.